{"id":77031,"date":"2026-02-03T12:04:24","date_gmt":"2026-02-03T12:04:24","guid":{"rendered":"https:\/\/english.saigonbiz.com\/vn\/biosion-announces-first-patient-dosed-in-investigator-initiated-phase-1-trial-of-bsi-082-a-next-generation-anti-sirp%ce%b1-monoclonal-antibody-for-advanced-solid-tumors\/"},"modified":"2026-02-03T12:04:24","modified_gmt":"2026-02-03T12:04:24","slug":"biosion-announces-first-patient-dosed-in-investigator-initiated-phase-1-trial-of-bsi-082-a-next-generation-anti-sirp%ce%b1-monoclonal-antibody-for-advanced-solid-tumors","status":"publish","type":"post","link":"https:\/\/english.saigonbiz.com\/vn\/biosion-announces-first-patient-dosed-in-investigator-initiated-phase-1-trial-of-bsi-082-a-next-generation-anti-sirp%ce%b1-monoclonal-antibody-for-advanced-solid-tumors\/","title":{"rendered":"Biosion Announces First Patient Dosed in Investigator-Initiated Phase 1 Trial of BSI-082, a Next-Generation Anti-SIRP\u03b1 Monoclonal Antibody for Advanced Solid Tumors"},"content":{"rendered":"<div>\n<p><b>Milestone validates the clinical potential of BSI-082 as a synergistic combination partner for antibody-drug conjugates (ADCs) and reinforces Biosion&#8217;s &#8220;In Global, For Global&#8221; collaboration strategy.<\/b><\/p>\n<p><span class=\"legendSpanClass\"><span class=\"xn-location\">NEWARK, Del.<\/span> and <span class=\"xn-location\">NANJING<\/span>, <span class=\"xn-location\">China<\/span><\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">Feb. 3, 2026<\/span><\/span> \/PRNewswire\/ &#8212; Biosion, Inc. (&#8220;Biosion&#8221;), a global, clinical-stage biotechnology company developing innovative antibody-based therapeutics, today announced that the first patient has been dosed in a Phase 1a\/<span class=\"xn-money\">1b<\/span> Investigator-Initiated Trial (IIT) evaluating BSI-082, a highly differentiated, fully human anti-SIRP\u03b1 monoclonal antibody. The study is sponsored by and being conducted at the <b>Mays Cancer Center, <\/b>a National Cancer Institute (NCI)-designated Cancer Center and part of The <span class=\"xn-org\">University of Texas at San Antonio&#8217;s<\/span> Health Science Center.<\/p>\n<p>This clinical milestone highlights the medical community&#8217;s strong interest in Biosion&#8217;s oncology assets and follows the company&#8217;s recent transformative partnership with Aclaris Therapeutics for its immunology portfolio.<\/p>\n<p><b>Collaborating to Unlock Innate Immunity<\/b><\/p>\n<p>BSI-082 is engineered to block the CD47-SIRP\u03b1 &#8220;don&#8217;t eat me&#8221; signal, a critical checkpoint tumor cells use to evade macrophage phagocytosis. Unlike other candidates in the class, BSI-082 was designed using Biosion&#8217;s proprietary <b>H\u00b3 Antibody Discovery Platform<\/b> to overcome historical development challenges.<\/p>\n<p><b>Key differentiators of BSI-082 include:<\/b><\/p>\n<ul type=\"disc\">\n<li><b>Broad Population Coverage:<\/b>\u00a0High-affinity binding to SIRP\u03b1 variants V1, V2, and V8, covering &gt;90% of the human population.<\/li>\n<li><b>Superior Safety Profile:<\/b>\u00a0Engineered Fc domain minimizes binding to red blood cells (RBCs) and platelets, significantly reducing the risk of anemia and thrombocytopenia often seen with anti-CD47 therapies.<\/li>\n<li><b>Preserved\u00a0T-Cell Function:<\/b>\u00a0No binding to SIRP\u03b3, ensuring that adaptive immune responses remain active and uninhibited.<\/li>\n<\/ul>\n<p>&#8220;The initiation of this trial by a premier institution like the Mays Cancer Center serves as powerful validation of BSI-082&#8217;s scientific rationale and therapeutic potential,&#8221; said <b>Mingjiu Chen, Ph.D., Founder and CEO of Biosion<\/b>. &#8220;BSI-082&#8217;s unique profile\u2014specifically its ability to potently block the &#8216;don&#8217;t eat me&#8217; signal without compromising patient safety\u2014positions it as an ideal combination partner for standard-of-care therapies, particularly antibody-drug conjugates (ADCs). We are honored to support Dr. Sarantopoulos and his team in this study, which represents a key step in our strategy to maximize the value of our oncology assets through high-quality clinical partnerships.&#8221;<\/p>\n<p><b>Study Design and Strategic Combinations<\/b><\/p>\n<p>The Phase 1a\/<span class=\"xn-money\">1b<\/span> study is an open-label, dose-escalation and dose-expansion trial designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of BSI-082 in patients with locally advanced or metastatic solid tumors.<\/p>\n<ul type=\"disc\">\n<li><b>Phase 1a:<\/b>\u00a0Will establish the Recommended Dose for Expansion (RDE) of BSI-082 as a monotherapy.<\/li>\n<li><b>Phase <span class=\"xn-money\">1b<\/span>:<\/b>\u00a0Will evaluate BSI-082 in combination with <b>trastuzumab deruxtecan (T-DXd)<\/b> in patients with HER2-positive solid tumors. Preclinical data has demonstrated that SIRP\u03b1 blockade can synergistically enhance the antitumor activity of ADCs by promoting antibody-dependent cellular phagocytosis (ADCP).<\/li>\n<\/ul>\n<p>&#8220;Targeting the innate immune system via the SIRP\u03b1-CD47 axis offers a compelling therapeutic strategy for refractory tumors,&#8221; said <b><span class=\"xn-person\">John Sarantopoulos<\/span>, M.D.<\/b>, associate professor of medicine in the Division of Hematology and Oncology, medical oncologist, and principal investigator at the Mays Cancer Center. &#8220;We are excited to lead the clinical evaluation of BSI-082, whose design addresses key limitations of earlier generation agents. We look forward to exploring its potential to improve outcomes for patients, particularly in combination with ADCs.&#8221;<\/p>\n<p><b>About Biosion<\/b>\u00a0<\/p>\n<p>Biosion is a global, clinical-stage biotechnology company dedicated to developing innovative antibody therapies to improve outcomes for patients with immunological and oncological diseases. By leveraging its proprietary core technology platforms\u2014including the<b> H\u00b3 Antibody Discovery <\/b>platform, the <b>SynTracer\u00ae HT Endocytosis<\/b> platform, and the<b> Flexibody\u00ae<\/b> Bispecific platform\u2014the company develops highly differentiated innovative medicines to address significant unmet medical needs worldwide. Through its flexible &#8220;Discover-Develop-Partner&#8221; model, Biosion has established<b> over 10 <\/b>global partnerships, with<b> 9 programs<\/b> currently in clinical development. These include monoclonal antibodies, bispecific antibodies, and antibody-drug conjugates (ADCs). Biosion maintains integrated operations across <span class=\"xn-location\">the United States<\/span>, <span class=\"xn-location\">China<\/span>, and <span class=\"xn-location\">Australia<\/span>. For more information, please visit <u><a href=\"https:\/\/www.biosion.com\/\" target=\"_blank\" rel=\"nofollow\" style=\"color: #0000FF\">www.biosion.com<\/a><\/u>.<\/p>\n<p>CONTACT:<br \/>PR: Josie Zhou,\u00a0<a href=\"mailto:Josie.Zhou@biosion.com\" target=\"_blank\" rel=\"nofollow\" style=\"color: #0000FF\">Josie.Zhou@biosion.com<\/a><br \/>BD: Anthony Yeh,\u00a0<a href=\"mailto:Anthony.Yeh@biosion.com\" target=\"_blank\" rel=\"nofollow\" style=\"color: #0000FF\">Anthony.Yeh@biosion.com<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Milestone validates the clinical potential of BSI-082 as a synergistic combination partner for antibody-drug conjugates (ADCs) and reinforces Biosion&#8217;s &#8220;In Global, For Global&#8221; collaboration strategy. NEWARK, Del. and NANJING, China, Feb. 3, 2026 \/PRNewswire\/ &#8212; Biosion, Inc. (&#8220;Biosion&#8221;), a global, clinical-stage biotechnology company developing innovative antibody-based therapeutics, today announced that the first patient has been [&#8230;]\n","protected":false},"author":1,"featured_media":85254,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-77031","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-pr-newswire"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v21.6 (Yoast SEO v21.6) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Biosion Announces First Patient Dosed in Investigator-Initiated Phase 1 Trial of BSI-082, a Next-Generation Anti-SIRP\u03b1 Monoclonal Antibody for Advanced Solid Tumors - Biz and Live in Saigon<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/english.saigonbiz.com\/vn\/biosion-announces-first-patient-dosed-in-investigator-initiated-phase-1-trial-of-bsi-082-a-next-generation-anti-sirp\u03b1-monoclonal-antibody-for-advanced-solid-tumors\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Biosion Announces First Patient Dosed in Investigator-Initiated Phase 1 Trial of BSI-082, a Next-Generation Anti-SIRP\u03b1 Monoclonal Antibody for Advanced Solid Tumors\" \/>\n<meta property=\"og:description\" content=\"Milestone validates the clinical potential of BSI-082 as a synergistic combination partner for antibody-drug conjugates (ADCs) and reinforces Biosion&amp;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/english.saigonbiz.com\/vn\/biosion-announces-first-patient-dosed-in-investigator-initiated-phase-1-trial-of-bsi-082-a-next-generation-anti-sirp\u03b1-monoclonal-antibody-for-advanced-solid-tumors\/\" \/>\n<meta property=\"og:site_name\" content=\"Biz and Live in Saigon\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/SaigonbizGroup\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-03T12:04:24+00:00\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/biosion-announces-first-patient-dosed-in-investigator-initiated-phase-1-trial-of-bsi-082-a-next-generation-anti-sirp%ce%b1-monoclonal-antibody-for-advanced-solid-tumors\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/biosion-announces-first-patient-dosed-in-investigator-initiated-phase-1-trial-of-bsi-082-a-next-generation-anti-sirp%ce%b1-monoclonal-antibody-for-advanced-solid-tumors\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\"},\"headline\":\"Biosion Announces First Patient Dosed in Investigator-Initiated Phase 1 Trial of BSI-082, a Next-Generation Anti-SIRP\u03b1 Monoclonal Antibody for Advanced Solid Tumors\",\"datePublished\":\"2026-02-03T12:04:24+00:00\",\"dateModified\":\"2026-02-03T12:04:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/biosion-announces-first-patient-dosed-in-investigator-initiated-phase-1-trial-of-bsi-082-a-next-generation-anti-sirp%ce%b1-monoclonal-antibody-for-advanced-solid-tumors\/\"},\"wordCount\":674,\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"articleSection\":[\"Pr Newswire\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/biosion-announces-first-patient-dosed-in-investigator-initiated-phase-1-trial-of-bsi-082-a-next-generation-anti-sirp%ce%b1-monoclonal-antibody-for-advanced-solid-tumors\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/biosion-announces-first-patient-dosed-in-investigator-initiated-phase-1-trial-of-bsi-082-a-next-generation-anti-sirp%ce%b1-monoclonal-antibody-for-advanced-solid-tumors\/\",\"name\":\"Biosion Announces First Patient Dosed in Investigator-Initiated Phase 1 Trial of BSI-082, a Next-Generation Anti-SIRP\u03b1 Monoclonal Antibody for Advanced Solid Tumors - Biz and Live in Saigon\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\"},\"datePublished\":\"2026-02-03T12:04:24+00:00\",\"dateModified\":\"2026-02-03T12:04:24+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/biosion-announces-first-patient-dosed-in-investigator-initiated-phase-1-trial-of-bsi-082-a-next-generation-anti-sirp%ce%b1-monoclonal-antibody-for-advanced-solid-tumors\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/english.saigonbiz.com\/vn\/biosion-announces-first-patient-dosed-in-investigator-initiated-phase-1-trial-of-bsi-082-a-next-generation-anti-sirp%ce%b1-monoclonal-antibody-for-advanced-solid-tumors\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/biosion-announces-first-patient-dosed-in-investigator-initiated-phase-1-trial-of-bsi-082-a-next-generation-anti-sirp%ce%b1-monoclonal-antibody-for-advanced-solid-tumors\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/english.saigonbiz.com\/vn\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Biosion Announces First Patient Dosed in Investigator-Initiated Phase 1 Trial of BSI-082, a Next-Generation Anti-SIRP\u03b1 Monoclonal Antibody for Advanced Solid Tumors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"name\":\"Biz and Live in Saigon\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\",\"name\":\"SaigonBiz Media\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"width\":512,\"height\":512,\"caption\":\"SaigonBiz Media\"},\"image\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/SaigonbizGroup\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"caption\":\"admin\"},\"sameAs\":[\"https:\/\/english.saigonbiz.com\/vn\"],\"url\":\"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Biosion Announces First Patient Dosed in Investigator-Initiated Phase 1 Trial of BSI-082, a Next-Generation Anti-SIRP\u03b1 Monoclonal Antibody for Advanced Solid Tumors - Biz and Live in Saigon","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/english.saigonbiz.com\/vn\/biosion-announces-first-patient-dosed-in-investigator-initiated-phase-1-trial-of-bsi-082-a-next-generation-anti-sirp\u03b1-monoclonal-antibody-for-advanced-solid-tumors\/","og_locale":"en_US","og_type":"article","og_title":"Biosion Announces First Patient Dosed in Investigator-Initiated Phase 1 Trial of BSI-082, a Next-Generation Anti-SIRP\u03b1 Monoclonal Antibody for Advanced Solid Tumors","og_description":"Milestone validates the clinical potential of BSI-082 as a synergistic combination partner for antibody-drug conjugates (ADCs) and reinforces Biosion&","og_url":"https:\/\/english.saigonbiz.com\/vn\/biosion-announces-first-patient-dosed-in-investigator-initiated-phase-1-trial-of-bsi-082-a-next-generation-anti-sirp\u03b1-monoclonal-antibody-for-advanced-solid-tumors\/","og_site_name":"Biz and Live in Saigon","article_publisher":"https:\/\/www.facebook.com\/SaigonbizGroup","article_published_time":"2026-02-03T12:04:24+00:00","author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/english.saigonbiz.com\/vn\/biosion-announces-first-patient-dosed-in-investigator-initiated-phase-1-trial-of-bsi-082-a-next-generation-anti-sirp%ce%b1-monoclonal-antibody-for-advanced-solid-tumors\/#article","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/biosion-announces-first-patient-dosed-in-investigator-initiated-phase-1-trial-of-bsi-082-a-next-generation-anti-sirp%ce%b1-monoclonal-antibody-for-advanced-solid-tumors\/"},"author":{"name":"admin","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6"},"headline":"Biosion Announces First Patient Dosed in Investigator-Initiated Phase 1 Trial of BSI-082, a Next-Generation Anti-SIRP\u03b1 Monoclonal Antibody for Advanced Solid Tumors","datePublished":"2026-02-03T12:04:24+00:00","dateModified":"2026-02-03T12:04:24+00:00","mainEntityOfPage":{"@id":"https:\/\/english.saigonbiz.com\/vn\/biosion-announces-first-patient-dosed-in-investigator-initiated-phase-1-trial-of-bsi-082-a-next-generation-anti-sirp%ce%b1-monoclonal-antibody-for-advanced-solid-tumors\/"},"wordCount":674,"publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"articleSection":["Pr Newswire"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/english.saigonbiz.com\/vn\/biosion-announces-first-patient-dosed-in-investigator-initiated-phase-1-trial-of-bsi-082-a-next-generation-anti-sirp%ce%b1-monoclonal-antibody-for-advanced-solid-tumors\/","url":"https:\/\/english.saigonbiz.com\/vn\/biosion-announces-first-patient-dosed-in-investigator-initiated-phase-1-trial-of-bsi-082-a-next-generation-anti-sirp%ce%b1-monoclonal-antibody-for-advanced-solid-tumors\/","name":"Biosion Announces First Patient Dosed in Investigator-Initiated Phase 1 Trial of BSI-082, a Next-Generation Anti-SIRP\u03b1 Monoclonal Antibody for Advanced Solid Tumors - Biz and Live in Saigon","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#website"},"datePublished":"2026-02-03T12:04:24+00:00","dateModified":"2026-02-03T12:04:24+00:00","breadcrumb":{"@id":"https:\/\/english.saigonbiz.com\/vn\/biosion-announces-first-patient-dosed-in-investigator-initiated-phase-1-trial-of-bsi-082-a-next-generation-anti-sirp%ce%b1-monoclonal-antibody-for-advanced-solid-tumors\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/english.saigonbiz.com\/vn\/biosion-announces-first-patient-dosed-in-investigator-initiated-phase-1-trial-of-bsi-082-a-next-generation-anti-sirp%ce%b1-monoclonal-antibody-for-advanced-solid-tumors\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/english.saigonbiz.com\/vn\/biosion-announces-first-patient-dosed-in-investigator-initiated-phase-1-trial-of-bsi-082-a-next-generation-anti-sirp%ce%b1-monoclonal-antibody-for-advanced-solid-tumors\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/english.saigonbiz.com\/vn\/"},{"@type":"ListItem","position":2,"name":"Biosion Announces First Patient Dosed in Investigator-Initiated Phase 1 Trial of BSI-082, a Next-Generation Anti-SIRP\u03b1 Monoclonal Antibody for Advanced Solid Tumors"}]},{"@type":"WebSite","@id":"https:\/\/english.saigonbiz.com\/vn\/#website","url":"https:\/\/english.saigonbiz.com\/vn\/","name":"Biz and Live in Saigon","description":"","publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/english.saigonbiz.com\/vn\/#organization","name":"SaigonBiz Media","url":"https:\/\/english.saigonbiz.com\/vn\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","width":512,"height":512,"caption":"SaigonBiz Media"},"image":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/SaigonbizGroup"]},{"@type":"Person","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","caption":"admin"},"sameAs":["https:\/\/english.saigonbiz.com\/vn"],"url":"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/77031","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/comments?post=77031"}],"version-history":[{"count":0,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/77031\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media\/85254"}],"wp:attachment":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media?parent=77031"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/categories?post=77031"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/tags?post=77031"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}